XBiotech Inc. announced the publication of results from its pivotal phase 3 trial of the Company's lead monoclonal antibody therapy. The results were published in The Lancet Oncology in an article titled, 'MABp1 as a Novel Antibody Treatment for Advanced Colorectal Cancer: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study. The article is now available online. Colorectal cancer is the second leading cause of malignancy in the industrialized world. Because the incidence of colorectal cancer increases with economic development and aging, incidence is rising worldwide. In Europe, approximately 470,000 patients will be diagnosed with colorectal cancer this year, and half will progress and ultimately succumb to the disease. Disease progression is associated with significant morbidity, functional impairment and failure of multiple therapies, often with substantial toxicities. People with advanced disease are thus symptomatic and often unable to tolerate further treatment-related side effects, leaving an urgent need for more effective, less toxic therapies for these patients.